Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways

Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways

Liver fibrosis is considered an epidemic health problem since it can lead to several insults that can be fatal. Remogliflozin (Remo), an inhibitor of the sodium–glucose cotransporter 2 (SGLT2) protein, is one of the most recently developed antidiabetic drugs for treating type 2 diabetes mellitus (T2...

Full description

Saved in:
Bibliographic Details
Main Authors: Naif ALSuhaymi, Mahdi H. Alsugoor, Aya A. Shokry, Hany M. Fayed, Bassim M. S. A. Mohamed, Sherif M. Afifi, Tuba Esatbeyoglu, Reda M. S. Korany, Marawan A. Elbaset
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Pharmacology
Subjects:
liver fibrosis
thioacetamide
Nrf2
SIRT1
oxidative stress
remogliflozin
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1586231/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1586231/full

Similar Items